Moreover, Se supplementation for 3 - 12 months reduced TPO-Ab and Tg-Ab titres in patients with HT, while levothyroxine (LT4) therapy was found to only impact TPO-Ab titres (22, 23). The gene discussed is TG; the disease is hematocrit.